Ultrasonographically elastometry by Fibroscan is a device that non-invasively evaluates the liver.

Liver disease is a silent epidemic, affecting millions of Americans and imposing significant financial burden on the U.S. healthcare system. Not simply a result of alcohol consumption, as many believe, non-alcoholic fatty liver disease (NAFLD) is the most common type of liver disease in the Western world — associated with obesity, insulin resistance, diabetes and other metabolic risk factors and directly related to too much fat in the liver cells. The American Liver Foundation estimates that about 100 million Americans — over 30 percent of the U.S. population — have NAFLD. If this trend continues, NAFLD will become the main indication for liver transplants in the country, with the number of healthy livers available for transplants likely to decline. Evaluating this early and proactively gives us an opportunity to predict and reverse liver disease and complements other biomarkers collected to assess liver health.